Current filters:


Popular Filters

8080 to 8104 of 8762 results

Forest Lab’s profit slumps nearly 13%, but sales up 9%


US drugmaker Forest Laboratories (NYSE: FRX) has posted disappoint results for its fiscal second quarter…

FinancialForest LaboratoriesPharmaceutical

Superior combo therapies to sustain HIV/AIDS market growth despite major patent expiries


The HIV/AIDS therapeutics market is a growing therapy sector, with the USA dominating in terms of revenues.…

Anti-viralsGlobalMarkets & MarketingPatentsPharmaceutical

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates


US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new…

Biogen IdecBiotechnologyElanImmunologicalsNeurologicalPharmaceuticalResearchTysabri

Mylan settles with Warner Chilcott over Femcon


US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it, along with Famy Care, has entered into…

Femcon FeGenericsLegalMylan LaboratoriesNorth AmericaPatentsRespiratory and PulmonaryWarner Chilcott

Autistic disorder therapeutics market set to grow to $5.5 billion by 2018


The autism spectrum disorder (ASD) therapeutics market was valued at $3.1 billion in 2010 and is forecast…

Markets & MarketingNeurologicalPharmaceutical

US Senators Kohl and Grassley urge “Super Committee” to encourage generic competition


As the USA’s Joint Select Committee on Deficit Reduction - dubbed the “Super Committee”…

GenericsHealthcareNorth AmericaPatentsPharmaceuticalPolitics

Johnson & Johnson beats forecasts, despite profit downturn in 3rd-qtr 2011


US health care giant Johnson & Johnson (NYSE: JNJ), first of the US pharma majors to report third-quarter…

FinancialJohnson & JohnsonPharmaceutical

Top EU firms increase investment in innovation, but lag behind global competitors


The European Commission's 2011 EU Industrial R&D Investment Scoreboard shows that R&D investment by top…


Lux Biosciences withdraws European marketing application for uveitis drug Luveniq


The European Medicines Agency has been formally notified by the European subsidiary of USA-based biotech…

BiotechnologyEuropeLuveniqLux BiosciencesOphthalmicsPharmaceuticalRegulation

Flutiform review to take longer than expected, says SkyePharma


UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization…

EuropeFlutiformMundi InternationalPharmaceuticalRegulationRespiratory and PulmonarySkyepharma

Australian coalition government announces A$55 million commitment to biotechnology


Australia’s Minister for Technology, Gordon Rich-Phillips this week released a new A$55 million…


GlaxoSmithKline may be ready to acquire Human Genome, newspaper reports


Shares of the UK’s biggest pharmaceuticals group, GlaxoSmithKline (LSE: GSK) amid revived speculation…

BenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMergers & AcquisitionsPharmaceutical

Angel Biotech proposes joint venture with Russia’s Materia Medica


Scotland-based Angel Biotechnology (ABH: LON) saw its shares leap 20% to 0.28 pence on Monday after it…

Angel BiotechnologyBiotechnologyEuropeMateria MedicaMergers & Acquisitions

Could hypertension drugs help people with Alzheimer's?


Within the next 20 years it is expected the number of people with Alzheimer's disease in the UK will…


Acute coronary syndrome drug market to reach around $2.8 billion in 2020


The uptake of oral agents with novel modes of action such as AstraZeneca’s ADP receptor antagonist…

Cardio-vascularGlobalMarkets & MarketingPharmaceutical

Roche to boost hep C offerings with $230 million acquisition of Anadys Pharma


In a further move to broaden in presence outside its current domination in the oncology sector, Swiss…

Anadys PharmaceuticalsAnti-viralsMergers & AcquisitionsPharmaceuticalRoche

UK NICE draft guidance recommends Eli Lilly’s Bydureon for type 2 diabetes


The UK drugs watchdog the National Institute of Health and Clinical Excellence (NICE) today published…

BydureonDiabetesEli LillyEuropePharmaceuticalPricingRegulation

Second Indian generics deal for SA’s Litha, this one with Micro Labs


In a second deal with an Indian drugmaker, South Africa’s Litha Healthcare has signed an exclusive…

Asia-PacificGenericsLicensingLitha HealthcareRest of the World

AstraZeneca and Forest initiate Ph III trials of CAZ-AVI


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and USA-based Forest Laboratories (NYSE: FRX) said this…

Antibiotics and Infectious diseasesAstraZenecaavibactamCeftazidimeForest LaboratoriesPharmaceuticalResearch

Another stab at obesity drug approval, as VIVUS resubmits Qnexa to the FDA


In the long-running battle to gets its obesity drug cleared for marketing, VIVUS (Nasdaq: VVUS) said…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationVivus

Pfizer updates Acura on Oxecta commercialization plans


US pharma behemoth Pfizer (NYSE: PFE) has commenced executing its commercialization plan for Oxecta (oxycodone…

Acura PharmaceuticalsLicensingMarkets & MarketingNeurologicalNorth AmericaOxectaPfizerPharmaceutical

Takeda names Nycomed’s Jostein Davidsen as head of Emerging Markets


Swiss drugmaker Nycomed, the near $13 billion acquisition of which was recently completed by Japan’s…

ManagementNycomedPharmaceuticalTakeda Pharmaceuticals

Daiichi Sankyo research exec points out “a lot of hype” around biomarkers


Robert Beckman, executive director, clinical development oncology at Japanese drug major Daiichi Sankyo…

Daiichi SankyoOncologyPharmaceuticalResearch

8080 to 8104 of 8762 results

Back to top